CXCR4 and graft versus host disease: In the current study, we demonstrate that, compared to WT-MSCs, MSCs stably expressing both CXCR4 and IL-10 exert enhanced therapeutic effects in a humanized model of GvHD, strongly suggesting that these cells will constitute a novel advanced therapy medicinal product with enhanced anti-GvHD therapeutic properties.